Skip to search formSkip to main contentSkip to account menu

Metastatic Squamous Cell Carcinoma

A squamous cell carcinoma which has spread from its original site of growth to another anatomic site.
National Institutes of Health

Related topics

Related topics

5 relations
Epithelial CellsEpitheliumMalignant Epithelial CellNeoplastic Cell

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective…
Adding cetuximab to chemotherapy improved survival in patients with recurrent/metastatic squamous cell carcinoma of the head and… 
Review
2014
Review
2014
The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal
Metastatic squamous cell carcinoma (SCCA) of the anal canal is a rare malignancy for which no standard treatment algorithm exists… 
Highly Cited
2013
Highly Cited
2013
Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.
BACKGROUND We evaluated combined targeting with cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody… 
Highly Cited
2010
Highly Cited
2010
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell…
BACKGROUND The phase III EXTREME study demonstrated that combining cetuximab with platinum/5-fluorouracil (5-FU) significantly… 
Highly Cited
2009
Highly Cited
2009
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
PURPOSE To compare survival in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) treated… 
Highly Cited
2005
Highly Cited
2005
Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Purpose: An objective response rate of 11% was reported in patients with recurrent and/or metastatic squamous cell carcinoma of… 
Highly Cited
2003
Highly Cited
2003
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
PURPOSE The epidermal growth factor receptor (EGFR) is a mediator of squamous cell carcinoma of the head and neck (SCCHN… 
Highly Cited
2001
Highly Cited
2001
Oncologic Rationale for Bilateral Tonsillectomy in Head and Neck Squamous Cell Carcinoma of Unknown Primary Source
OBJECTIVE: To demonstrate an oncologic basis for the recommendation to perform bilateral tonsillectomy as a routine measure in… 
Review
1994
Review
1994
Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.
Paclitaxel is a new anticancer agent with a novel mechanism of action. It promotes polymerisation of tubulin dimers to form… 
Highly Cited
1991
Highly Cited
1991
Cisplatin and 5‐fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin
Seven patients with advanced locoregional or metastatic squamous cell carcinoma of the skin were treated with cis… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)